Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$489K Sell
4,065
-42
-1% -$4.85K 0.22% 45
2025
Q4
$432K Buy
4,107
+34
+0.8% +$3.19K 0.2% 46
2025
Q3
$342K Buy
4,073
+373
+10% +$30.7K 0.16% 51
2025
Q2
$293K Buy
3,700
+36
+1% +$2.86K 0.15% 53
2025
Q1
$329K Buy
3,664
+29
+0.8% +$2.71K 0.17% 49
2024
Q4
$362K Sell
3,635
-28
-0.8% -$2.89K 0.19% 44
2024
Q3
$416K Buy
3,663
+22
+0.6% +$2.61K 0.24% 38
2024
Q2
$451K Buy
3,641
+9
+0.2% +$1.16K 0.28% 34
2024
Q1
$479K Buy
3,632
+17
+0.5% +$2.1K 0.32% 32
2023
Q4
$394K Buy
3,615
+437
+14% +$45.4K 0.27% 33
2023
Q3
$327K Buy
3,178
+19
+0.6% +$2.05K 0.29% 26
2023
Q2
$365K Buy
3,159
+19
+0.6% +$2.16K 0.31% 24
2023
Q1
$334K Buy
3,140
+93
+3% +$10K 0.33% 25
2022
Q4
$338K Buy
3,047
+22
+0.7% +$2.25K 0.36% 24
2022
Q3
$261K Buy
3,025
+90
+3% +$8.03K 0.28% 28
2022
Q2
$268K Buy
2,935
+22
+0.8% +$1.95K 0.26% 29
2022
Q1
$239K Buy
2,913
+22
+0.8% +$1.74K 0.21% 34
2021
Q4
$222K Buy
+2,891
New +$230K 0.16% 35

Other funds holding MRK

PFS Partners's MRK Position: Q1 2026 in Review

PFS Partners reduced its Merck (MRK) stake by 1% in Q1 2026, selling an estimated $4.85K and leaving 4,065 shares worth $489K. The position accounts for 0.22% of the portfolio, ranked #45.

PFS Partners first reported a position in MRK in Q4 2021 and has held it in 18 quarters since. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • PFS Partners held 4,065 shares of Merck worth $489K as of Q1 2026.
  • PFS Partners sold 42 Merck shares in Q1 2026, an estimated $4.85K.
  • Merck made up 0.22% of PFS Partners's portfolio in Q1 2026, its #45 holding.
  • PFS Partners first reported a position in Merck in Q4 2021 and has held it in 18 quarters since.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on PFS Partners's 13F filing for Q1 2026, filed 9 Apr 2026.